| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 07/28/2005 | US20050164950 Orally administered small peptides synergize statin activity |
| 07/28/2005 | US20050164920 Compounds that modulate neuronal growth and their uses |
| 07/28/2005 | US20050164909 Methods and reagents for treating inflammation and fibrosis |
| 07/28/2005 | US20050164380 Stem cell culture medium and method of using said medium and the cells |
| 07/28/2005 | US20050164283 Mesoporous permeation layers for use on active electronic matrix devices |
| 07/28/2005 | US20050163870 plant extracts used for treating and prevention of prostate gland and urogenital disorders in humans |
| 07/28/2005 | US20050163835 Gefitinib or salt with and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether; increased absorption and/or bioavailability and may reduce inter-patient variability; prevents precipitation in higher pH upper GI |
| 07/28/2005 | US20050163764 oral administration and mucosal administration and wherein the gastrointestinal injury is treated; bacterial infection and cancer treatments that can cause tissue damage |
| 07/28/2005 | US20050163749 Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 07/28/2005 | US20050163744 Novel method for down-regulation of amyloid |
| 07/28/2005 | US20050163720 May be used to prepare novel aerosol formulations, and can be advantageous in terms of improving the stability of the aerosol formulation, reducing drug deposition, increasing shelf life |
| 07/27/2005 | EP1556694A2 Method of isolation and self-assembly of small protein particles from blood and other biological materials |
| 07/27/2005 | EP1556513A2 Compositions and methods for treating human papillomavirus-mediated disease |
| 07/27/2005 | EP1556379A2 Chemical compounds |
| 07/27/2005 | EP1556374A2 Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
| 07/27/2005 | EP1556362A2 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 07/27/2005 | EP1556081A2 Recombinant intracellular pathogen immunogenic compositions and methods for use |
| 07/27/2005 | EP1556069A2 Methods and formulations comprising agonists and antagonists of nuclear hormone receptors |
| 07/27/2005 | EP1556062A2 Herbal extract comprising a mixture of saponins obtained from sapindus trifoliatus for anticonvulsant activity |
| 07/27/2005 | EP1556040A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| 07/27/2005 | EP1556030A2 Taxane metabolites |
| 07/27/2005 | EP1556015A1 Extended, controlled release pharmaceutical compositions comprising charged polymers |
| 07/27/2005 | EP1556010A2 Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
| 07/27/2005 | EP1309555B1 Process for making amlodipine maleate |
| 07/27/2005 | EP1287004B1 Synthetic process for the manufacture of an ecteinascidin compound |
| 07/27/2005 | EP0981323B1 Desensitizing dentifrice having limited astringency |
| 07/27/2005 | CN1646528A Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
| 07/27/2005 | CN1646163A Administration of agents for the treatment of inflammation |
| 07/27/2005 | CN1646133A Pharmaceutical combinations of cox-2 inhibitors and opiates |
| 07/27/2005 | CN1646121A Methods for modulating phototoxicity |
| 07/27/2005 | CN1644693A Protein having tpo activity |
| 07/21/2005 | WO2005044194A3 TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR |
| 07/21/2005 | WO2005041873A3 Formulation of exendin-4 |
| 07/21/2005 | WO2005039494A3 Inhibitors of rnase p proteins as antibacterial compounds |
| 07/21/2005 | WO2005037228A3 Halogen phosphonate monoesters |
| 07/21/2005 | WO2005037226A3 Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders |
| 07/21/2005 | WO2005037212A3 Treatment of chemical dependency with substantially nonaddicting normorphine and norcodeine derivatives |
| 07/21/2005 | WO2005027826A3 Methods and treating severe acute respiratory syndrome |
| 07/21/2005 | WO2005020935A3 Method and composition of administering radioprotectants |
| 07/21/2005 | WO2005020911A3 Benzo[1, 3]dioxole compounds, pharmaceutical compositions thereof, and processes of making and using the same |
| 07/21/2005 | WO2005020907A3 Ocular drug delivery device |
| 07/21/2005 | WO2005018561A3 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
| 07/21/2005 | WO2005013905A3 SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| 07/21/2005 | WO2005011607A3 Treatment of cancers expressing p95 erbb2 |
| 07/21/2005 | WO2004091520A3 Methods and compositions for treating atherosclerosis |
| 07/21/2005 | WO2004091506A3 Taxane-based compositions and methods of use |
| 07/21/2005 | WO2004087059A3 Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding |
| 07/21/2005 | WO2004087051A3 Ophthalmic compositions for treating ocular hypertension |
| 07/21/2005 | WO2004087045A3 Devices, methods, and compositions to prevent restenosis |
| 07/21/2005 | WO2004060274A3 Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells |
| 07/21/2005 | US20050159471 Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system |
| 07/21/2005 | US20050159456 Method of treating of demyelinating diseases or conditions |
| 07/21/2005 | US20050159450 Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics |
| 07/21/2005 | US20050159424 pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or C( .dbd. O)NR6, |
| 07/21/2005 | US20050159419 Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage |
| 07/21/2005 | US20050159416 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 1-[3-(1-Acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methoxy-pyridin-3-yl)-urea |
| 07/21/2005 | US20050159391 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs |
| 07/21/2005 | US20050159356 Glucagon-like peptide-1 (GLP-1); for treatment of diabetes, obesity, excessive appetite, insufficient satiety, and metabolic disorders; for converting liver stem/progenitor cells into functional pancreatic cells |
| 07/21/2005 | US20050158401 Associated with decreased nitric oxide bioavailability; using an arginine- and/or arginase-inhibitor based therapy; asthma, sickle cell disease, and pulmonary hypertension |
| 07/21/2005 | US20050158394 Oral administration of solid dosage forms; multiple unit dosing device comprising a housing and an actuator |
| 07/21/2005 | US20050158384 Sustained release delivery of amphetamine salts |
| 07/21/2005 | US20050158323 Via antibodies specific for antigen C35; host cells |
| 07/21/2005 | US20050158309 Gonadotropin-releasing hormone (gnrh); gene expression inhibition; for treatment of T-cell related neoplastic diseases |
| 07/21/2005 | US20050158275 Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture |
| 07/20/2005 | EP1554371A2 Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
| 07/20/2005 | EP1554311A2 Humanized antibodies that recognize beta amyloid peptide |
| 07/20/2005 | EP1554301A2 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
| 07/20/2005 | EP1554265A2 Compounds, compositions and methods |
| 07/20/2005 | EP1554235A2 Process for synthesizing l-y-methylene glutamic acid and analogs |
| 07/20/2005 | EP1553966A2 Human papillomavirus polypeptides and immunogenic compositions |
| 07/20/2005 | EP1553964A2 Ketoamide inhibitors in chronic nerve disease |
| 07/20/2005 | EP1553946A2 Enhancement of sleep with t-type calcium channel antagonists |
| 07/20/2005 | EP1553945A2 Nitroxide radioprotector formulations and methods of use |
| 07/20/2005 | EP1553937A2 Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods |
| 07/20/2005 | EP1553936A2 Treatment and rehydration composition which is used to limit the side effects of gastro-enteritis in adults |
| 07/20/2005 | EP1303514B1 Process for preparing azacycloalkanoylaminothiazoles |
| 07/20/2005 | EP1028701B1 Use of ascorbic acid in permanent waving and hair coloring compositions |
| 07/20/2005 | EP0910571B1 Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| 07/20/2005 | CN1643138A Novel cytokine ZCYTOR17 ligand |
| 07/20/2005 | CN1642966A Isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
| 07/20/2005 | CN1642535A Tuberculosis treatment using pleuromutilin derivatives |
| 07/20/2005 | CN1640877A Novel spiro compounds |
| 07/20/2005 | CN1211367C Prostaglandin agonists and their use to treat bone disorders |
| 07/20/2005 | CN1211365C Novel salt of perindopril and pharmacetuical composition contg. same |
| 07/19/2005 | US6919450 Process for the preparation of benazepril |
| 07/19/2005 | US6919094 Composition of medicine for treating headache disease and process of preparation and uses thereof |
| 07/19/2005 | US6919087 And an excipient wherein the pH is within the range of 5.5-7.0; stability; dosage forms |
| 07/14/2005 | WO2005063278A1 Surface protection of exposed biological tissues |
| 07/14/2005 | WO2005063169A2 Medical lipolysis of fat accumulations |
| 07/14/2005 | WO2005055944A9 Oligosaccharide compositions and use thereof in the treatment of infection |
| 07/14/2005 | WO2005046612A3 Hydroxy piperidine derivatives to treat gaucher disease |
| 07/14/2005 | WO2005046584A3 Stimulation of hair growth by ginkgo biloba flavanoids |
| 07/14/2005 | WO2005044188A3 Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
| 07/14/2005 | WO2005044175A3 Desensitization of complement activation using monocyte/macrophage inhibitory compounds |
| 07/14/2005 | WO2005043971A3 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 07/14/2005 | WO2005037187A3 High affinity ligands for influenza virus and methods for their production |
| 07/14/2005 | WO2005034855A3 Photodynamic inactivation of bacterial spores |
| 07/14/2005 | WO2005034837A3 7H-IMIDAZO [1,2-α] PYRAZIN-8-ONE COMPOUNDS AS ION CHANNEL MODULATORS |
| 07/14/2005 | WO2005030150A3 9,10-α,α-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THEREOF |
| 07/14/2005 | WO2005025491A3 Water-soluble polyamioamides as sunscreen agents |